US Stock Insider Trading | Cimbaro Amit Holdings disclosed 6 insider trading transactions on February 24

robot
Abstract generation in progress

On February 24, 2026, Zimmer Biomet Holdings (ZBH) disclosed six insider transactions. Director Tornos Ivan sold 8,846 shares on February 20, 2026.

[Recent Insider Transactions]

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
February 24, 2026 Director Tornos Ivan February 20, 2026 Sell 8,846 98.62 872,400
February 24, 2026 Executive Winkler Lori February 20, 2026 Sell 683 98.62 67,400
February 24, 2026 Executive Stellato Paul A February 20, 2026 Sell 362 98.62 35,700
February 24, 2026 Executive Upadhyay Suketu February 20, 2026 Sell 2,446 98.62 1,212,400
February 24, 2026 Executive Phipps Chad F February 20, 2026 Sell 942 98.62 92,900
February 24, 2026 Executive VAN ZUILEN WILFRED February 20, 2026 Sell 638 98.62 62,900
February 17, 2026 Executive Yi Sang December 12, 2025 Sell 1,000 96.49 96,500
December 3, 2025 Executive Winkler Lori November 28, 2025 Sell 179 97.52 17,500
November 12, 2025 Executive Upadhyay Suketu November 10, 2025 Sell 4,731 87.73 415,100
September 15, 2025 Executive Yi Sang September 11, 2025 Sell 1,200 103.59 124,300

[Company Profile]

Zimmer Biomet Holdings was incorporated in Delaware in 2001. Its history dates back to 1927 when its predecessor, Zimmer Manufacturing Company, was founded in Warsaw, Indiana. The company is a global leader in medical technology, offering a comprehensive product portfolio aimed at maximizing mobility and improving health outcomes. It designs, manufactures, and sells orthopedic reconstruction products; sports medicine, biologics, limb and trauma products; craniofacial and thoracic products; surgical products; and a suite of integrated digital and robotic technologies utilizing data, data analytics, and artificial intelligence.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin